Facing the flu and RSV season can be especially daunting for those with weakened immune systems. But here's the good news: the Infectious Diseases Society of America (IDSA) has updated its guidelines, offering crucial advice to protect immunocompromised individuals.
The IDSA's updated guidelines focus on flu and respiratory syncytial virus (RSV) vaccines, particularly emphasizing safety for those with compromised immune systems. These guidelines are a response to the growing need for clear, evidence-based direction during respiratory virus season.
Who are we talking about? Immunocompromised individuals include those with conditions like hematologic cancers, primary immunodeficiencies, HIV with severe immunosuppression, or those who have undergone organ transplants, stem cell transplants, CAR-T therapy, or chemotherapy. These individuals are at a higher risk of severe illness from these infections.
The updated guidelines provide specific recommendations on the use of live-attenuated flu vaccines. A key takeaway: these vaccines, like FluMist, should not be administered to immunocompromised patients and should be avoided by those in close contact with individuals who are severely immunosuppressed.
"We are in the midst of respiratory virus season, and vaccines are an effective tool to protect people with compromised immunity," says Dr. Lindsey Robert Baden, vice president of clinical research at Mass General Brigham and chair of IDSA’s guideline panel. The panel, comprised of experts in infectious diseases, oncology, transplantation, immunology, pediatrics, and HIV, focused on the critical question of whether each vaccine should be used in immunocompromised patients. They evaluated key outcomes such as hospitalization, death, severe illness, and serious side effects.
The panel reviewed evidence published between 2023 and mid-2025, using a systematic review and applying the GRADE framework to assess the quality of evidence and the strength of each recommendation. For COVID-19, the panel advises administering an FDA-approved vaccine as soon as possible, with a second dose likely to extend protection, and encourages household members to stay up to date.
Vaccine effectiveness in immunocompromised patients has been shown to significantly reduce hospitalizations, critical illness, and death, with few serious outcomes reported. Flu vaccination is recommended annually, with high-dose or adjuvanted vaccines offering stronger immune responses for those with weakened immune systems. RSV vaccination is recommended for adults and adolescents, with solid organ transplant candidates ideally vaccinated before their transplant.
For children under 18 years, vaccination decisions should be made through shared decision-making. It's safe to administer COVID-19, flu, and RSV vaccines simultaneously, although timing should be carefully considered when patients are undergoing immunosuppressive therapy, a transplant, chemotherapy, or biologics.
The guidelines also stress the importance of reducing risk through antivirals, other preventive measures, and quick access to treatment. Vaccination plans should be personalized, with close coordination with doctors and attention to household vaccination.
But here's where it gets controversial... Research is still needed on immune responses, optimal dosing schedules, long-term effectiveness, and rare side effects. What are your thoughts on these guidelines? Do you agree with the recommendations, or do you have a different perspective? Share your thoughts in the comments below!
These guidelines provide a roadmap for protecting immunocompromised patients from serious illness, empowering both doctors and patients to make informed vaccination decisions.
